ShareValue scores for 0M0F.LSE: Valuation 29, Quality 29, Growth 50, Health 48.

0M0F.LSE
LSE

Tandem Diabetes Care, Inc.

£0.19(-4.05%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-7% to 11%
Valuation
29
Overvalued
Price vs Value
Quality
29
Weak
Business Strength
Growth
50
Moderate
Revenue & Earnings
Health
48
Moderate
Financial Stability
Momentum
26
Bearish
Price Trend

Company Details

About

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026